Key result
ICD implantation shows no long-term survival benefit over usual care in non-ischemic HFrEF.
Why the study?
ICDs prevent sudden cardiac death but do not protect against other causes of death, which may change over time in heart failure patients, warranting long-term studies.
Does ICD implantation reduce all-cause death in patients with non-ischemic heart failure with reduced ejection fraction?
RCT (n=1,116)
Does ICD implantation reduce all-cause death in patients with non-ischemic heart failure with reduced ejection fraction?
Extended 13-year follow-up of the DANISH trial confirms that ICD implantation does not reduce all-cause mortality in patients with non-ischemic heart failure with reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
No long-term mortality benefit from ICD in non-ischemic HFrEF; confirms DANISH results and reinforces medical therapy as primary strategy.
Introduction An implantable cardioverter-defibrillator (ICD) can prevent sudden cardiac death caused by ventricular tachyarrhythmia, severe bradycardia, or complete heart block but cannot provide protection against other causes of death. However, the most common causes of death may change over time in patients with heart failure (HF). Therefore, there is a rationale for long-term studies. Objectives We examined the effect of ICD implantation on long-term mortality in patients with non-ischemic HF with reduced ejection fraction enrolled in the DANISH trial, which randomized patients to ICD implantation or usual care. Methods The DANISH trial enrolled 1,116 patients with non-ischemic HF, left ventricular ejection fraction <35%, New York Heart Association functional class II-III (class IV if cardiac resynchronization therapy was planned), and elevated natriuretic peptide levels. In the main trial, patients were followed until death or June 30, 2016, whichever came first (median follow-up 5.6 years). The primary outcome was all-cause death, and secondary outcomes were cardiovascular death and sudden cardiovascular death. In the main trial, ICD implantation did not reduce the risk of all-cause death compared with usual care, but there was an interaction between age and the effect of ICD implantation, such that an ICD reduced the risk of all-cause death in patients <70 years, but not in those >70 years. In this study with extended follow-up, patients were followed until death or January 31, 2024, whichever came first (median follow-up 13.2 years). Cardiovascular and sudden cardiovascular deaths are currently being adjudicated, but these data will be presented at the ESC Congress 2025. Results During a median follow-up of 13.2 years (25th-75th percentile, 11.6-14.6 years), 294 (52.9%) patients in the ICD group and 299 (53.4%) in the control group died. Compared with usual clinical care, ICD implantation did not significantly reduce the risk of all-cause death (HR 0.96 [95% CI, 0.82-1.13]). Overall, the effect of ICD implantation was similar across subgroups. Age no longer significantly modified the effect of ICD implantation on all-cause death, but there was a numerical trend towards a greater benefit of ICD implantation among individuals younger than 59 years. Conclusions During a median follow-up of 13.2 years, ICD implantation did not reduce all-cause death in patients with non-ischemic HF with reduced ejection fraction. Data on cardiovascular and sudden cardiovascular death will be presented at the ESC Congress 2025.
No takes yet. Share an insight, caveat, or question.
Butt et al. (2025) conducted an RCT in Non-ischemic heart failure with reduced ejection fraction (n=1,116). ICD implantation vs. Usual care was evaluated on All-cause death (HR 0.96, 95% CI 0.82-1.13). Over a median follow-up of 13.2 years, ICD implantation did not reduce the risk of all-cause death compared with usual care in patients with non-ischemic HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: